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Abstract
Fish are an important model for the pharmacological and toxicological characterization of human pharmaceuticals in drug
discovery, drug safety assessment and environmental toxicology. However, do fish respond to pharmaceuticals as humans
do? To address this question, we provide a novel quantitative cross-species extrapolation approach (qCSE) based on the
hypothesis that similar plasma concentrations of pharmaceuticals cause comparable target-mediated effects in both
humans and fish at similar level of biological organization (Read-Across Hypothesis). To validate this hypothesis, the
behavioural effects of the anti-depressant drug fluoxetine on the fish model fathead minnow (Pimephales promelas) were
used as test case. Fish were exposed for 28 days to a range of measured water concentrations of fluoxetine (0.1, 1.0, 8.0, 16,
32, 64 mg/L) to produce plasma concentrations below, equal and above the range of Human Therapeutic Plasma
Concentrations (HTPCs). Fluoxetine and its metabolite, norfluoxetine, were quantified in the plasma of individual fish and
linked to behavioural anxiety-related endpoints. The minimum drug plasma concentrations that elicited anxiolytic
responses in fish were above the upper value of the HTPC range, whereas no effects were observed at plasma
concentrations below the HTPCs. In vivo metabolism of fluoxetine in humans and fish was similar, and displayed bi-phasic
concentration-dependent kinetics driven by the auto-inhibitory dynamics and saturation of the enzymes that convert
fluoxetine into norfluoxetine. The sensitivity of fish to fluoxetine was not so dissimilar from that of patients affected by
general anxiety disorders. These results represent the first direct evidence of measured internal dose response effect of a
pharmaceutical in fish, hence validating the Read-Across hypothesis applied to fluoxetine. Overall, this study demonstrates
that the qCSE approach, anchored to internal drug concentrations, is a powerful tool to guide the assessment of the
sensitivity of fish to pharmaceuticals, and strengthens the translational power of the cross-species extrapolation.
Citation: Margiotta-Casaluci L, Owen SF, Cumming RI, de Polo A, Winter MJ, et al. (2014) Quantitative Cross-Species Extrapolation between Humans and Fish: The
Case of the Anti-Depressant Fluoxetine. PLoS ONE 9(10): e110467. doi:10.1371/journal.pone.0110467
Editor: Jodi Pawluski, Ohio University, United States of America
Received August 1, 2014; Accepted September 11, 2014; Published October 22, 2014
Copyright:  2014 Margiotta-Casaluci et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. The authors confirm that all the data
underlying the findings are fully available from the Dryad database. DOI:10.5061/dryad.b1772.
Funding: This work was funded by a Biotechnology and Biological Sciences Research Council (BBSRC) Research Grant (BB/100646X/1), co-funded by the
AstraZeneca Global Environment research programme, to JPS and MR-W supporting LM-C. AdP was supported by the Isambard Scholarship awarded by Brunel
University. BBSRC had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SFO is an employee of
AstraZeneca; RIC, MJW and GHP were also AstraZeneca employees. AstraZeneca provided support in the form of salaries for authors SFO, RIC, MJW and GHP and
grant to JPS and MR-W supporting LM-C, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation
of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Competing Interests: This work was co-funded by the AstraZeneca Global Environment research programme. SFO is an employee of AstraZeneca; RIC, MJW
and GHP were also AstraZeneca employees. AstraZeneca is a biopharmaceutical company specialized in the discovery, development, manufacturing and
marketing of prescription medicines, including some anxiolytic products. This does not alter our adherence to all the PLoS ONE policies on sharing data and
materials.
* Email: Luigi.Margiotta-Casaluci@brunel.ac.uk
Introduction
Cross-species extrapolation of biological processes represents a
cornerstone in pharmacology and toxicology, both of which are
intimately dependent on its reliability to accurately predict
therapeutic and harmful effects of chemical substances in humans
or other recipient species. However, extrapolating the quantitative
relationship between pharmacological or toxicological responses
and levels of chemical exposure, from one species to another,
remains one of the key challenges for the development of high-
power and low-risk predictive approaches [1,2]. Classically, the
extrapolation is applied from the model species (e.g. rodents) to
humans using appropriate scaling factors (e.g. safety margins) that
take into account inter-species differences in metabolism, physi-
ology, genetics, and biochemistry [3]. For example, animal
experiments are used to estimate Acceptable Daily Intake (ADI)
values for chemicals in food and drinking water [4,5], and to
perform the pre-clinical safety assessment of pharmaceuticals [6].
On the other hand, when the extrapolation is aimed at the
environmental risk assessment (ERA) of chemicals applied to
wildlife (e.g. aquatic organisms) the results of toxicity experiments,
conducted using a limited selection of test species, are extrapolated
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to tens or hundreds of species potentially living within the same
ecosystem [7].
In the last two decades, the field of ERA has been posing a
conceptual challenge to the cross-species extrapolation process,
due to presence of human pharmaceuticals in the aquatic
environment [8–11]. The increasing number of pharmaceuticals
detected in surface waters (e.g. rivers) has attracted interest in
recent years because these compounds, despite being present at
very low concentrations (sub-ng/L to few mg/L), are selected to
interact with high affinity with specific human biological targets
(e.g. receptors, enzymes). These targets can be evolutionary
conserved and functional also in aquatic organisms (especially in
fish) [12], suggesting that the interaction drug/target may
theoretically lead to unwanted pharmacological (and potentially
toxicological) effects in non-target species exposed to pharmaceu-
ticals in the environment. This potential scenario, combined with
the fact that for many pharmaceuticals there are vast amounts of
data generated on their pharmacology and toxicology during and
after the development phase [13], led to the development of an
alternative extrapolation framework, known as ‘‘Read-Across’’
[11]. This approach centres on the exploitation of clinical and
non-clinical data to predict potential effects in wildlife species, and
it has been praised by a number of authors over recent years,
particularly with respect to fish [11,13–15].
Although this approach in its present form is largely theoretical,
supporting experimental data are emerging to suggest that Read-
Across, coupled with bioinformatics and with the use of biological
databases, could become one of the most promising approaches to
predict potential adverse effects induced by pharmaceuticals in
non-target species [11,16,17]. Nonetheless, the Read-Across
approach in its present formulation is mainly qualitative, whereas
qualitative extrapolations between species are not robust enough
to drive decision-making, allow the generation of inter-species
safety margins for drug safety assessment or provide quantitative
indicators of environmental risk.
Here we provide a novel quantitative cross-species extrapolation
approach (qCSE) based on the Read-Across hypothesis [11,18].
Assuming the evolutionary and functional conservation of
molecular targets in fish, the hypothesis states that human
pharmaceuticals will elicit the same target-mediated pharmaco-
logical response in fish as they do in humans, that the
pharmacological responses will precede the toxicological ones,
and that target-mediated effects at a comparable level of biological
organization will occur at similar plasma (or tissue) concentrations
(i.e. Human Therapeutic Plasma Concentration, HTPC) [11].
According to this hypothesis, it should be possible to use the
relationship between internal concentrations (either measured or
predicted) in the target (i.e. human) and non-target (i.e. fish)
organisms to predict the likelihood of an effect occurring.
Currently no comprehensive validation of the Read-Across
Hypothesis exists [11]; therefore, in our study, the behavioural
effects of the anti-depressant drug fluoxetine on the fish model
fathead minnow (Pimephales promelas) were used as test case.
Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) anti-
depressant used globally for over 25 years to treat major
depression and other psychiatric disorders, and which has been
frequently detected at low concentrations in the aquatic environ-
ment [19]. Critically, the primary pharmacological target, the
serotonin transporter, is evolutionary and functionally conserved
in fish [20], and fluoxetine has previously been reported to affect
fish behaviour [21,22]. In particular, as SSRIs are recognised
anxiolytics used to treat Generalised Anxiety Disorder (GAD) in
humans [23,24] and anxiogenic/anxiolytic responses are well
characterized in adult fish [25,26]. Anxiety-related behaviour was
selected as an appropriate endpoint in order to test and compare
Mode-of-Action (MoA) driven effects between target and non-
target species [21]. In particular, fluoxetine-induced anxiolytic
responses in fish were hypothesised as functionally equivalent to
the reduction of anxiety in human patients following fluoxetine
treatment.
We exposed fish to a range of water concentrations of fluoxetine
predicted to produce plasma concentrations below, equal and
above the ones known to induce therapeutic effects in humans (i.e.
HTPC). We then measured the drug plasma concentrations in
individual fish and linked them to anxiety-related endpoints
quantified using automated video-tracking software. The aim of
the study was to assess whether behavioural responses were
induced by fluoxetine at plasma concentrations higher, equal or
lower than HTPCs. Our results demonstrated that fluoxetine
induces behavioural effects in fish as it does in humans, but only
when its blood levels are similar to those effective in patients,
hence validating the Read-Across hypothesis. Overall we show
that the qCSE approach, anchored to the plasma concentration of
drug, is a powerful tool to guide the assessment of the sensitivity of
fish to pharmaceuticals, and strengthens the translational power of
the cross-species extrapolation.
Materials and Methods
Ethics statement
This study was carried out at AstraZeneca (UK) under Project
License and Personnel Licences granted by the UK Home Office
under the United Kingdom Animals Act (Scientific Procedures),
and also in accordance with AstraZeneca’s local and global ethical
policies.
Test species
Adult male fathead minnows (Pimephales promelas), approxi-
mately 6 months old (weight: 2.961 g) were supplied from stocks
maintained at AstraZeneca and kept according to the UK Animal
Scientific Procedures Act guidelines.
Test chemical and dilution water
Fluoxetine hydrochloride (CAS number 56296-78-7), was
obtained from VWR (supplier US Pharmacopeia) as .99% pure.
Concentrated stock solutions were prepared weekly in reverse
osmosis water. Dechlorinated tap water (5 and 10 mm carbon
filtered) was used as dilution water. Temperature was maintained
at 2561uC for the duration of the study. Dissolved oxygen
concentrations remained above 80% of the air saturation value
throughout the exposures and the pH was 7.560.5. The hardness
of the dilution water was ,200 mg L21, as CaCO3, and residual
chlorine was ,0.01 mg L21.
Experimental design and exposure protocol
The 28-day experiment was carried out using a continuous
flow-through system comprised of 9.5 L glass tanks. Thermostat-
ically heated (2561uC) dechlorinated tap water flowed into eight
glass mixing chambers at a rate of 333.3 mL/min. The same
chambers also received the stock solution of the test chemical via
peristaltic pump at a rate of 0.1 mL/min, in order to achieve the
desired nominal concentrations. Separate glass lines from each
mixing chamber supplied about 12 tank volume changes per day
to each of four replicate test tanks, each containing five male fish
(20 fish per treatment).
The final experimental setup included eight treatment groups.
Due to the high variability of behavioural responses, two
independent sets of dilution water control groups were used (C1
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and C2) in order to increase the statistical power of the
experiment. Moreover, six different fish groups were exposed to
six concentrations of fluoxetine (0.1, 1.0, 8.0, 16, 32, 64 mg/L),
selected to cover both environmentally-relevant concentrations
and pharmacologically relevant ones. The selection of test water
concentrations was also driven by the application of the Fish
Plasma Model [18] (as detailed in the following section), which
predicted resulting fish plasma concentrations respectively below
(groups: 0.1, 1.0, 8.0 mg/L), within (groups: 8.0, 16 mg/L), and
above (groups: 32, 64 mg/L) the Human Therapeutic Range of
fluoxetine. The latter was generated by a clinical trial in which
patients were treated for 30 days with daily administration of
fluoxetine (40 mg). This dosing regimen produced plasma
concentrations of fluoxetine in the range 91–302 ng/mL and
norfluoxetine in the range 72–258 ng/mL (FDA, Application
No. 18-936/SE5-064). The duration of the clinical trial (30-days)
was very close to the duration of the fish exposure experiment
described here (28 days).
Both the allocation of the treatment groups in the experimental
room and the allocation of each fish into one of the 32 tanks were
performed randomly using random number generator software.
Due to the large number of fish and treatments, and to the time
required to perform the subsequent behavioural tests, the
allocation of the fish to the experimental tanks was performed
over two days, as was the final sampling. During the study, fish
were fed three times per day, once with adult brine shrimp
(Tropical Marine Centre, Gamma irradiated) and twice with pellet
food (Bio-Optimal C80, Brande, Denmark). The test was run at
2561uC, with 16 h light/8 h dark photoperiod, and with 20 min
dawn/dusk transition periods.
Prediction of fluoxetine plasma concentrations by the
Fish Plasma Model
Measured plasma concentrations were compared to the
concentrations predicted by the Fish Plasma Model. The model
aims to predict the Fish Steady State Plasma Concentration
(FSSPC) of a drug starting from a given water concentration, and is
based on the following equations:
Log PBlood:Water~0:73|Log D7:4{0:88 ð1Þ
FSSPC~Water concentration, mg=L½ |PBlood:Water ð2Þ
In the original model equation (2) includes the Log KOW instead
of the Log D7.4. However, Valenti and collaborators [27]
demonstrated that water pH significantly affects the ionization,
bioavailability, and toxicity of SSRIs. For this reason, fluoxetine
Log D7.4 (1.99; [28]) was used to run the model instead of the Log
KOW (4.09; predicted by ALOGPS).
The nominal water concentrations of fluoxetine were used in
Equation (2) to drive the selection of the exposure concentration;
whereas the water concentrations measured on Day 28 were used
to compare measured versus predicted plasma concentrations.
Analysis of fish behaviour
Methodological rationale for the selection of the Novel
Tank Diving Test. The ‘‘Novel Tank Diving Test’’ is
conceptually similar to the rodent open field test. It is based on
the instinctive behaviour of fish to seek protection when they are
transferred to a novel and unfamiliar environment (i.e. observation
tank) by diving to the bottom and remaining in an alert status until
the environmental conditions are perceived as safe enough to
initiate exploration of the new environment. In this test, fish are
individually transferred from the home tank to the novel
environment, which is represented by a clean observation tank
containing water that has not previously been exposed to other
fish. The swimming pattern is then analysed by separating the
main area into two or three different sub-areas (e.g. bottom,
middle, top) in post hoc video analysis (Figure 1). Several
behavioural endpoints are quantified to assess anxiety (e.g. number
of transitions into the top area, time spent in the top area). Many
of these endpoints are strictly correlated with the height at which
the fish swims in the tank (Figure 1). This measure is considered a
very powerful measure of anxiety, and notably, it can be compared
to the thymogtaxis observed in rodents, defined as the response of
an organism to physical contact or to the proximity of a physical
discontinuity in the environment (e.g. rats preferring to swim near
the edge of a water maze) [29].
Novel Tank Diving Test and Automated video-tracking of
fathead minnow behavior. The behavioural test apparatus
consisted of five glass observation tanks (30563556210 mm;
L6H6D) filled with 10.0 L of water. All the sides of the tanks,
except the observational one, were covered with white paper in
order to enhance the contrast between fish and background, to
facilitate the software video analysis, and to avoid visual
disturbance to the fish. One Fujifilm Digital Camera (FinePix
JV300, 14.0 Mpix) was positioned in front of each observation
tank.
On Day 28, each behavioural trial started with the random
selection of one of the experimental tanks. The only exception to
the random selection was represented by the test of one control
group at the beginning of the day (i.e. C1) and one at the end (i.e.
C2). This was necessary in order to exclude the time of the day as
a source of difference in fish behavioural responses (e.g. fish tested
at 9 am vs the ones tested at 5 pm). Then the water in the
observation tanks was spiked with the appropriate volume of
fluoxetine stock solution in order to reach a fluoxetine concentra-
tion equal to the one present in the selected exposure tank, thus
avoiding potential loss of drug from fish blood during the duration
of the behavioural test. All the five fish in the tank were gently
collected and individually allocated to one of the five observation
tanks. Fish behaviour in response to the novel environment was
recorded for 20 minutes, and was initiated within 30 seconds from
the allocation of the last fish.
At the end of the trial, fish were quickly removed from the
observation tanks, and terminally anaesthetised according to UK
Home Office regulations using a buffered ethyl 3-aminobenzoate
methanesulfonate solution (MS-222, 0.5 g/L; pH 7.5) (Sigma,
Poole, UK; CAS No: 144-55-8). Immediately after termination,
wet weight (to the nearest 0.0001 g) and standard length (to the
nearest 0.1 mm) were recorded, and these parameters were used
to calculate the condition index (CI). Blood samples were collected
from each fish via the caudal artery/vein using 75 mL heparinised
haematocrit capillary tubes, which were subsequently centrifuged
at 14,0006g for 5 min at 4uC in order to determine the
haematocrit fraction and to separate the plasma fraction. The
latter was collected (typically between 10 and 50 mL) and
individually transferred to a 96-well plate for the analytical
quantification of fluoxetine and norfluoxetine. Lastly, the brain
and liver were rapidly dissected, weighed (to the nearest 0.0001 g),
and snap frozen in liquid nitrogen before being stored at 280uC.
The liver weight was used to calculate the hepatosomatic index
(HSI). The sequence described above was performed by a team of
operators working in parallel. This guaranteed that all the blood
samples were collected within three minutes from the fish
Anxiolytic Effects of Fluoxetine in Humans and Fish
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termination, thus minimizing any potential metabolic alteration of
the concentration of fluoxetine and of its metabolite, norfluoxetine.
At the end of each trial on a group of 5 fish, the water in the
observation tanks was discarded, the tanks were washed
thoroughly using clean water, and clean water (10 L) was
dispensed in each tank. This precaution was adopted in order to
avoid any potential chemical communication between the tested
fish and the following one occurring through the release of alarm
pheromones into the water, or through faeces. The next trial was
then initiated, repeating the entire procedure described above.
The VideoTrack analysis software (Version 2.5.0.25, View-
Point, Lyon, France) was used for the offline analysis of fish
exploratory behaviour. The observation tank was visually divided
in three areas of equal size (bottom, middle, top), and the following
seven endpoints were quantified for a period of 20 min: number of
entries into the top area (T-Top), number of entries into the middle
area (T-Middle), percentage of time spent in the top area (Time-
Top), percentage of time spent in the middle area (Time-Middle),
distance travelled in the top area (Dist-Top), distance travelled in
the middle area (Dist-Middle), total distance travelled (Dist-Tot),
and swim velocity (Speed).
As well as assessing behaviour at the end of the experiment, the
same behavioural test was performed on Day 14 on two out of four
replicate tanks per treatment group (n = 10), with the exception
that fish were not terminated after the test, but were reassigned to
the original exposure tank. The tested tanks were selected by using
a random number generator.
Weekly behavioural observations. To investigate whether
the geotaxis response observed during the Novel Tank Diving Test
was also detectable in the exposure tanks, an operator performed a
semi-quantitative and blind analysis of group behaviour on videos
recorded in each exposure tank. On Day 0, 6, 12, 18, 24 fish were
recorded for 25 min in their exposure tank using Fujifilm Digital
Camera (FinePix JV300, 14.0 Mpix) positioned in front of the
tanks. The video-recording were performed one hour after
feeding, twice a day at 1 pm and 7 pm. Since no intra-day
differences in the group behaviour were observed, only the videos
recorded at 1 pm were analysed blindly by an independent
operator not involved in the research project. The analysis was
performed for 12 min, from minute 10 to minute 22 of each video,
and consisted in recording the number of seconds during which a
minimum of three fish out of five were in the upper area of the
exposure tank. This endpoint was selected after the qualitative
observation, in a previous experiment, that fish treated with
100 mg fluoxetine/L spent more time swimming in the upper part
of the tank than control fish.
Quantification of fluoxetine in water
Water samples (5–10 mL) were collected from each fish tank on
day -1, 1, 7, 14, 21 and 28. Samples were diluted with an equal
volume of acetonitrile (ACN) containing 2.0 mg/L of the internal
standards: fluoxetine-d5 and norfluoxetine-d5. Samples were
analysed by liquid chromatography-mass spectrometry (LC-MS)
and quantified against known concentrations of fluoxetine-d5 and
norfluoxetine-d5. The details of the LC-MS apparatus and
protocol are provided in Table S1 and Table S2.
Quantification of fluoxetine and norfluoxetine in fish
plasma
Fish plasma samples (5 to 50 mL) were transferred to 96-
deepwell plate and 400 mL of ACN was added to each well.
Successively, samples were extracted by solid phase extraction
(SPE) using a Strata-X-C plate (Strata-X-C, 96-well, 30 mg,
Phenomenex, Torrance, California). Each plasma sample was
loaded to the SPE plate preconditioned with methanol and
equilibrated with ACN. The compounds were eluted with 1 mL
Figure 1. Methodological procedure for the quantification of fish behaviour. A) Experimental steps performed to quantify fish behavioural
response to a new environment following 14-day and 28-day exposure to fluoxetine. Anxiety-related behavioural endpoints were quantified using a
Novel Tank Diving Test. B) Example of different exploratory behaviours in a Novel Tank Diving Test. Inactive fish (left) versus active fish (right). The
different tracking colours indicate different speeds (black, slow; green, medium; red, fast).
doi:10.1371/journal.pone.0110467.g001
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5% ammonium hydroxide in CAN/i-propanol solution (50/50, v/
v). The elutes were collected in 1 mL plastic vials in a 96-well plate
array and evaporated to dryness under vacuum at 30uC. Samples
were reconstituted in 500 mL of ACN containing 2.0 mg/L of the
internal standards and 500 mL of HPLC water. Samples were then
analysed by LC-MS and quantified against known concentrations
of fluoxetine-d5 and norfluoxetine-d5. The details of the LC-MS
apparatus and protocol are provided in Table S1 and Table S2.
Spiked control plasma samples (20 mg/L) were prepared in
triplicate and were used to assess the extraction efficiency.
Statistical analysis
Statistical analyses were conducted using SPSS software (version
20, SPSS Inc, USA). Data were analysed for normality
(Kolmogorov–Smirnov test) and variance homogeneity (Levene’s
test). Where assumptions of normality and homogeneity were met,
one-way analysis of variance (ANOVA) was followed by the
Dunnett’s test to compare the treatment means with controls.
Where the assumptions were not met, data were transformed
((log(x+1)), and analysed using a non-parametric test, Kruskal–
Wallis ANOVA on Ranks, followed by Dunn’s post hoc test, and
by Wilcoxon-Rank-Sum Test [30]. Statistical significance was set
at a level of p,0.05, unless otherwise indicated.
Results
Water concentrations of fluoxetine
Concentrations of fluoxetine in water were in the expected
range for all treatment groups. Mean measured concentrations in
the 1, 8, 16, 32 and 64 mg/L groups were, respectively, 1.260.3,
9.161.3, 17.462.2, 41.768.0 and 72.569.3 mg/L. Fluoxetine
concentration in the 0.1 mg/L treatment group was below the
LOD (0.4 mg/L); however, the concentration of the dosing stock
used in the 0.1 mg/L treatment group was quantified on two
occasions during the study and was 100% of the nominal
concentration. Since the measured flow rates of the dosing stocks
and dilution water were equal to the nominal values for all the
treatments, it is assumed that the nominal water concentration was
also achieved in the 0.1 mg/L group. Concentrations of fluoxetine
in the control groups (C1 and C2) were below the LOD. Finally,
norfluoxetine concentrations were below the LOD (0.8 mg/L) in
all the water samples analysed.
Due to the importance of water concentrations to determine the
plasma concentration by the FPM, the water concentrations
measured on the sampling day (Day 28) will be used in this
manuscript. These values were 0.1, 1.1, 9.7, 19.6, 38.4, and
72.2 mg fluoxetine/L and are approximated to the nearest integer
(0.1, 1, 10, 20, 38, and 72 mg fluoxetine/L).
Fluoxetine uptake and metabolism
Fluoxetine was detected in fish plasma and was shown to be
transformed to the metabolite norfluoxetine. Fluoxetine and
norfluoxetine were successfully quantified in individual plasma
samples, allowing the assessment of the inter-individual variability
of drug uptake and its relationship with the biological effects. The
two target compounds were detected in all the fish, except those
exposed to 0.1 and 1 mg/L, in which the concentrations of the two
analytes were below the LOD and LOQ of the analytical method.
The uptake followed a bi-phasic concentration-dependent
kinetics (Figure 2). The lowest fluoxetine water concentrations
that produced quantifiable levels of fluoxetine and norlfuoxetine in
individual plasma samples was 10 mg fluoxetine/L. In this
treatment group the measured plasma concentrations were very
close to those predicted by the FPM, which was therefore also used
to predict plasma concentrations for the 0.1 and 1 mg/L treatment
groups. At water concentrations between 0.1 and 20 mg/L the
linear uptake was driven by the Log D7.4, as demonstrated by the
high accuracy of the FPM. However, at water concentrations
higher than 20 mg/L, the slope of the linear uptake changed
significantly (from 4.3 to 15.5), so that the measured plasma
concentrations were higher than those predicted. At 10 mg/L the
mean measured plasma concentrations were only 14% higher than
the predicted ones. This value increased to 32% at 20 mg/L, 63%
at 38 mg/L, and 71% at 72 mg/L.
The linear equation (R2 = 0.9992) describing the plasma uptake
of fluoxetine at water concentrations between 20 and 72 mg/L is
the following:
y~15:537x{197 ð3Þ
where ‘‘x’’ is the water concentration and ‘‘y’’ the plasma
concentration.
The described change in the slope of the uptake curve was
concomitant to the change in the ratio between norfluoxetine and
fluoxetine (NFLX:FLX) (Figure 2). At fluoxetine plasma concen-
trations between 0 and 100 ng/mL, the ratio NFLX:FLX was 4:1;
whereas above plasma concentrations of 100 ng/mL the ratio was
increasingly lower at increasing plasma concentrations. The lowest
NFLX:FLX value observed in this study was 2:1 and correspond-
ed to a plasma concentration of approximately 900 ng/mL.
Fish Plasma Concentrations vs Human Therapeutic
Plasma Concentrations
The HTPC range used as reference in this study was 91–
302 ng/mL for fluoxetine and 72–258 ng/mL for norfluoxetine
(FDA, Application No. 18-936/SE5-064).
Exposure of fish to 0.1, 1 and 10 mg/L resulted in plasma
concentrations of fluoxetine below the HTPC, whereas exposure to
20 and 38 mg fluoxetine/L produced plasma concentrations of
fluoxetine approximately equal to the lower and the higher values
of the HTPC range, respectively (Figure 2). On the other hand,
exposure to the highest concentration of fluoxetine (72 mg/L)
resulted in plasma concentrations between 3- and 10-fold above
the higher and the lower value of the HTPC range, respectively.
The mean plasma concentration of fluoxetine in those fish
(930 ng/mL) was just below the plasma concentration defined as
‘‘toxic’’ in humans (1000 ng/mL) [31]. However, four fish out of
twenty exceeded that value without showing any evident symptom
of toxicity (2632, 1664, 1052, 1037 ng/mL).
When norfluoxetine was considered, the relationship with the
HTPCs reflected the apparently higher metabolic capacity of fish
compared to humans in metabolising fluoxetine to norfluoxetine.
Indeed, differently from plasma fluoxetine, exposure to 10 mg
fluoxetine/L was sufficient to produce plasma concentrations of
norfluoxetine within the HTPC range. At the same time, exposure
to 20, 38 and 72 mg fluoxetine/L produce plasma concentrations
of norfluoxetine, respectively, 1.7-, 3.8-, and 7.3–fold above the
highest value of the HTPC range (258 ng/mL) (Figure 2).
Since in humans fluoxetine and norfluoxetine are considered
equipotent, the sum of the two compounds it is what should be
considered in order to properly interpret the biological effects.
Here we made the assumption that fluoxetine and nor-fluoxetine
are also equi-potent in fish. In doing so, it was possible to observe
that exposure to 0.1 and 1 mg fluoxetine/L resulted in plasma
concentrations of the two compounds that were below the lowest
value of the HTPC range. On the other hand, fish exposed to 10
and 20 mg/L had total plasma concentrations of the two
Anxiolytic Effects of Fluoxetine in Humans and Fish
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compounds very similar to, respectively, the lowest and the highest
value of the HTPC range (163 vs 208 ng/mL and 541 vs 560 ng/
mL). Lastly, the two top exposure concentrations corresponded to
plasma levels respectively 2.4 and 5-fold above the highest value of
the HTPC range.
Intra-group variability of drug uptake
The maximum observed inter-individual variability of plasma
concentrations in fish kept in the same exposure tank was 7.6-fold
difference between the minimum and the maximum measured
values for fluoxetine (Table 1), and 4-fold difference for norfluox-
etine (Table 2). When the four replicates per treatment were
combined, these values increase to 8.6-fold for fluoxetine
(Table 1), and 5.3-fold for norfluoxetine (Table 2). However, the
minor differences in the water concentration of fluoxetine among
the four replicate tanks during the study may account for this
apparent increase in variability. In most tanks, inter-individual
variability of drug plasma concentrations was consistently lower
than 3-fold [i.e. 11 out of 16 tanks for fluoxetine, and 15 out of 16
tanks for norfluoxetine]. There was no apparent water concen-
tration-dependent increase of variability for fluoxetine, whereas an
increasing trend can be observed for norfluoxetine. However, the
latter was closely related to inter-individual variability in fish
metabolism rather than to uptake processes.
Behavioural effects
The following seven endpoints were quantified for a period of
20 minutes: number of entries into the top area (T-Top); number
of entries into the middle area (T-Middle); percentage of time
spent in the top area (Time-Top); percentage of time spent in the
middle area (Time-Middle); distance travelled in the top area (Dist-
Top); distance travelled in the middle area (Dist-Middle); total
distance travelled (Dist-Tot), and swim velocity (Speed).
Novel Tank Diving Test – Day 14. After 14 Days of
exposure to fluoxetine, only fish exposed to the highest concen-
tration (72 mg/L) showed a significantly enhanced exploratory
behaviour of the novel environment. All the endpoints, except
Speed, were significantly different from the control values (p,0.01)
(Figure 3).
Novel Tank Diving Test – Day 28. On day 28, fish exposed
to the two highest concentrations of fluoxetine (38 and 72 mg/L)
explored the upper areas of the novel environment more
frequently and for longer time compared to the fish in the other
groups, confirming the anxiolytic effects of fluoxetine in fish
observed on Day 14 (Figure 4, Figure 5, Figure 6, Figure 7). Of
the seven behavioural endpoints considered in this study, all except
Speed were significantly affected in fish exposed to 72 mg
fluoxetine/L (p,0.01 for all the affected endpoints except for
the distance Dist-Middle, for which p=0.017), whereas the
exposure to 38 mg fluoxetine/L significantly affected only the
endpoints related to the Middle Area (T-Middle, p=0.03; Time-
Middle, p=0.013; Dist-Middle, p=0.016) (Figure 4). These results
Figure 2. Fluoxetine uptake and metabolism in fathead minnow following a 28-d study. A) Relationship between measured (red line;
mean 6 SD; n= 20) and predicted (dashed line) plasma concentrations of fluoxetine, based on concentrations quantified in the water. The predicted
plasma concentrations were generated by using the Fish Plasma Model [18]. B) Relationship between measured plasma concentrations of fluoxetine
(red line; mean 6 SD; n = 20) and norfluoxetine:fluoxetine ratio (grey line, mean 6 SD; n = 20). The change in the slope of the plasma concentration
curve corresponds to the decrease of the norfluoxetine:fluoxetine ratio, indicating inhibitory and/or saturation effects on the metabolic enzymes that
convert fluoxetine into norfluoxetine. C) Relationship between measured plasma concentrations of fluoxetine in fish plasma (mean 6 SD; n = 20) and
Human Therapeutic Plasma Concentration range (grey area, 91–302 ng/mL). D) Relationship between measured plasma concentrations of
norfluoxetine in fish plasma (mean 6 SD; n = 20) and Human Therapeutic Plasma Concentration range (grey area, 72–258 ng/mL).
doi:10.1371/journal.pone.0110467.g002
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suggest that 38 mg fluoxetine/L induced the fish to swim more
frequently in the Middle Area, but this effect was not strong
enough to induce fish to swim in the Top Area of the observation
tank (the furthest from the ‘‘safe’’ bottom area).
Both in the control and in the unaffected treatment groups (0.1,
1, 10, 20 mg/L) a high intra-group variability in the behavioural
responses was observed. A more detailed analysis revealed that
that variability was due to the presence of a few very active fish in
each group (i.e. dominant fish), including in the control. For
example, fish in control groups (C1 and C2) were often
characterized by ‘‘zero’’ values in all the endpoints related to the
exploration of the Top Area. On the other hand, the active fish,
independently from the treatment with fluoxetine, had very high
numeric values for the same endpoints. This implied that, when
mean values were considered, the very high values of the active
fish were ‘‘spread’’ among the zero values of the inactive fish,
Figure 3. Effect of fluoxetine on fish exploratory behaviour quantified during a Novel Tank Diving Test performed after 14 days of
exposure. A) Number of transitions into the Top Area; B) number of transitions into the Middle Area; C) time spent in the Top Area; D) time spent in
the Middle Area; E) distance travelled in the Top Area; F) distance travelled in the Middle Area. C1 and C2 indicate control group 1 and control group
2, respectively. Boxes represent medians (full line), with 5th and 95th percentiles (n=20). *p,0.05.
doi:10.1371/journal.pone.0110467.g003
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resulting in the apparent variability. This effect became even
clearer when median values were used instead of means, as
showed in Figure 7. This type of data visualization showed a clear
dose-response for all the endpoints related to the Top Area,
whereas the response of the endpoints related to the Middle Area
had higher noise, including in the control groups. This suggests
that the variability of those endpoints, rather than being a
mathematical artefact, had an actual biological meaning, and it
was possibly driven by the spatial proximity of the two areas
(Bottom and Middle), which increased the chances of fish
exploring them.
When the results obtained on Day 14 and on Day 28 were
compared, the behavioural response of fish in the highest
concentration group on Day 14 appeared to be more robust in
terms of magnitude than on Day 28, in particular if the number of
transitions in the Top and Middle Areas were considered. For
example, T-Top was 1436127 on Day 14 but only 43672 on Day
28. A similar difference was observed for T-Middle (2006185 vs
Figure 4. Relationship between plasma concentrations of fluoxetine and its effects on fish exploratory behaviour after 28 days of
exposure. Exploratory behaviour was quantified in individual fish using the Novel Tank Diving Test. A) Number of transitions into the Top Area; B)
number of transitions into the Middle Area; C) time spent in the Top Area; D) time spent in the Middle Area; E) distance travelled in the Top Area; F)
distance travelled in the Middle Area; G) speed. The Human Therapeutic Plasma Concentration range of fluoxetine plotted in the graphs is 91–
302 ng/mL. C1 and C2 indicate control group 1 and control group 2, respectively. The X-axis has a Log2 scale, while the Y-axis has a linear scale.
Values are plotted as mean 6 SD (n= 20). *: p,0.05.
doi:10.1371/journal.pone.0110467.g004
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826127). The reason for these differences may simply lie in the
variability of the response at different time points. Alternatively, it
is possible that fish tested on Day 14 received a lower degree of
stress than the ones tested on Day 28, because, although the
experimental protocol and the room used for the Novel Tank
Diving Test were the same in both days, the activity of the
operator in the exposure room during Day 28, which was the final
sampling day (i.e. to collect fish from the exposure tanks), may
have caused the observed differences in the magnitude of the
response. These differences highlight the sensitivity of the
behavioural responses to environmental factors, which, if not
accounted for in the experimental design, may significantly affect
the results obtained in behavioural tests performed on adult fish.
On the other hand, 38 mg fluoxetine/L affected fish behaviour
only after 28 days of treatment, whereas no response was observed
after 14 days, indicating a time-dependent decrease of the LOEC.
Weekly behavioural observations. The analysis of the
geotaxis response in fish groups revealed the high complexity of
Figure 5. Relationship between plasma concentrations of norfluoxetine and its effects on fish exploratory behaviour after 28 days
of exposure. Exploratory behaviour was quantified in individual fish using the Novel Tank Diving Test. A) Number of transitions into the Top Area; B)
number of transitions into the Middle Area; C) time spent in the Top Area; D) time spent in the Middle Area; E) distance travelled in the Top Area; F)
distance travelled in the Middle Area; G) speed. The Human Therapeutic Plasma Concentration range of fluoxetine plotted in the graphs is 72–
258 ng/mL. C1 and C2 indicate control group 1 and control group 2, respectively. The X-axis has a Log2 scale, while the Y-axis has a linear scale.
Values are plotted as mean 6 SD (n= 20). *: p,0.05.
doi:10.1371/journal.pone.0110467.g005
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group behaviour in fathead minnow, as well as the difficulty of its
interpretation. The group exploratory activity in the exposure tank
depends on a number of factors that all together produced a very
high inter-tank variability, even in the same treatment group. It is
possible to hypothesise that the high hierarchic structure of fathead
minnow groups, characterized by dominant/territorial and
subordinate fish, was one of the main sources of the observed
variability. On Day 24, in three out of four tanks in the highest
concentration group (72 mg/L), fish spent between 8.7 and
12 minutes in the upper third of the tank, confirming the geotaxis
response also when fish were kept in groups. However, also fish in
two replicate tanks in the control group C1 spent, respectively, 9.7
and 10 minutes in the top area. This result suggested that
habituation to the tank environment occurred, so that with the
Figure 6. Relationship between plasma concentrations of fluoxetine plus norfluoxetine and their effects on fish exploratory
behaviour after 28 days of exposure. Exploratory behaviour was quantified in individual fish using the Novel Tank Diving Test. A) Number of
transitions into the Top Area; B) number of transitions into the Middle Area; C) time spent in the Top Area; D) time spent in the Middle Area; E)
distance travelled in the Top Area; F) distance travelled in the Middle Area; G) speed. The Human Therapeutic Plasma Concentration range of
fluoxetine + norfluoxetine plotted in the graphs is 163–560 ng/mL. C1 and C2 indicate control group 1 and control group 2, respectively. The X-axis
has a Log2 scale, while the Y-axis has a linear scale. Values are plotted as mean 6 SD (n=20). *: p,0.05.
doi:10.1371/journal.pone.0110467.g006
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progress of the study some groups tended to explore more the
upper areas of the tank independently from the presence of a
chemical in the water. This natural behaviour overlapped with
fluoxetine-induced behaviour, complicating any reliable analysis of
the association between fluoxetine exposure and the observed
response. Once again, this observation may be linked to the
development of dominance in the fish group. For example, in
some cases the dominant fish was aggressively controlling the
bottom of the tank, and this behaviour induced the remaining fish
to swim in the upper areas.
Our results refer specifically to the visual analysis of fathead
minnow group behaviour. However, the use of alternative fish
Figure 7. Relationship between plasma concentrations of fluoxetine and behavioural endpoints expressed as median values.
Exploratory behaviour was quantified in individual fish using the Novel Tank Diving Test after 28 days of exposure. The dose-response of behavioural
endpoints appears to be visually more obvious when median values are used (in this figure) instead of mean values (Figure 4). This highlights the
important role of inter-individual variability in the interpretation of behavioural effects. A) Number of transitions into the Top Area; B) number of
transitions into the Middle Area; C) time spent in the Top Area; D) time spent in the Middle Area; E) distance travelled in the Top Area; F) distance
travelled in the Middle Area; G) speed. The Human Therapeutic Plasma Concentration range of fluoxetine plotted in the graphs is 91–302 ng/mL. C1
and C2 indicate control group 1 and control group 2, respectively. The X-axis has a Log2 scale, while the Y-axis has a linear scale. Values are plotted as
medians (n= 20). *: p,0.05.
doi:10.1371/journal.pone.0110467.g007
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species with weaker social hierarchies (e.g. zebrafish), together with
the use of specific software able to track multiple animals (e.g.
Zebralab, Viewpoint), may represent a successful solution to the
problem of the quantification of the effects of chemicals on group
behaviour.
Validation of the Read-Across Hypothesis
In this study, significant effects on the exploratory behaviour in
a novel environment were observed only in fish with plasma
concentrations of fluoxetine approximately equal to the highest
value of the fluoxetine HTPC range (1.360.8 fold) or higher
(361.7 fold). When the sum of fluoxetine and norfluoxetine was
considered, the previous values increase (2.460.9 fold and 562.5
fold respectively) above the highest value of the HTPC range.
These results indicate that the minimum plasma concentrations of
active metabolites required to elicit an anxiolytic response in fish
after 28 day of exposure to fluoxetine were close to the upper value
of the HTPC range. No effects in these fish were observed at
plasma concentration below the equivalent HTPCs. The relation-
ship between behavioural endpoints and plasma concentrations of
fluoxetine, norfluoxetine and fluoxetine+norfluoxetine are shown,
respectively, in Figure 4, Figure 5, and Figure 6.
Discussion
Estimating the sensitivity of model species to human pharma-
ceuticals is a fundamental aspect of pharmacology and toxicology.
To determine the sensitivity of fish to fluoxetine we investigated
the equivalence of the pharmacodynamic response between fish
and humans by testing experimentally the so called ‘‘Read-Across
Hypothesis’’ [11]. The question we tried to answer was whether
the same plasma concentrations of fluoxetine in both fish and
humans produce comparable target-mediated effects at similar
levels of biological organization, and if these effects occur only at
plasma concentration equal or higher than those that are effective
in humans. Our experiment successfully validated the Read-
Across Hypothesis, and demonstrated that fluoxetine elicits
anxiolytic responses in fish only when its plasma levels were
proximate to the higher values of human therapeutic plasma
concentration range, or higher.
Relationship between behavioural effects and drug
plasma concentrations
In humans, fluoxetine acts by inhibiting the serotonin trans-
porter (SERT) in the pre-synaptic cell, which in turn leads to
increased extracellular levels of serotonin in the synaptic cleft and
to the consequent activation of post-synaptic receptors [32]. The
overall clinical effect of elevated mood and decreased anxiety is
thought to be due to adaptive changes in neuronal function,
resulting in enhanced serotonergic neurotransmission. In fish,
SERT is highly conserved and shows 69% identity to the human
protein (94% if the aminoacids with known function in SSRIs
binding are considered) [20]. From the pharmacodynamics
standpoint, Gould and collaborators tested the ability of several
SSRIs to displace [3H]-citalopram bound to fathead minnow
SERT in vitro, reporting a ki value for fluoxetine in the low
nanomolar range (1165 nM) [33], which is not too dissimilar
from the ki values reported in a similar assay by Owens et al. [34]
for rat cortex (260.1 nM) and human transfected cells
(0.960.06 nM). These data allow us to hypothesise that similar
fluoxetine concentrations in the plasma (or at the target level) may
cause comparable pharmacodynamic response in both fish and
humans, leading to similar phenotypic responses at similar levels of
biological organization (i.e. anxiolytic behaviour).
Extrapolating behavioural effects between fish and humans may
appear an overambitious challenge for the cross-species extrapo-
lation, given the high complexity of human behaviour, and the
unquantifiable role of social factors in the response to the drug.
However, fish models and particularly zebrafish have acquired a
central role as model species for studying the molecular
mechanisms of behavioural pathologies, due to the high evolu-
tionary conservation of the neurotransmitter-related systems [35–
39]. The observation of complex stereotypical patterns in fish
behaviour, combined with the knowledge of the above-mentioned
systems, allowed the pharmacological dissection zebrafish behav-
ioural responses and is currently leading to an insightful
characterization of many chemical-induced behavioural responses
in fish (e.g. photomotor response, rest/wake behaviour, acoustic
startle, habituation) [40–45].
In our study, we focused our attention on an anxiety-related
behaviour of adult fish, which we selected as the most appropriate
endpoint to test and compare Mode-of-Action (MoA) driven
effects between fish and humans [21]. Fluoxetine-induced
anxiolytic responses in fish were hypothesised as functionally
equivalent to the reduction of anxiety in human patients following
fluoxetine treatment. Fluoxetine exposure elicited anxiolytic
responses in fathead minnow, and the highest concentration
(72 mg/L) induced fish to visit more frequently and for more time
the upper part of the tank, whereas half of that concentration,
interestingly, enhanced fish exploratory behaviour only up to the
middle area of the tank, demonstrating that the geotaxis response
is dose-dependent. The lowest concentration that induced a
significant behavioural response was 38 mg/L, corresponding to
plasma concentrations of fluoxetine and fluoxetine+norfluoxetine,
respectively, 1.3- fold and 2.4-fold above the highest value of the
HTPC range. Several studies have demonstrated that fish respond
in a consistent way to both anxiolytic and anxiogenic compounds
[21,22,26,46,47], and exposure of zebrafish to 100 mg fluoxetine/
L for 7 days is generally used as the standard treatment in studies
comparing the potency of chemicals in inducing anxiolytic or
anxiogenic effects [25]. This concentration increased the time
spent by zebrafish in the upper part of the tank and the number of
transitions into the top area [25,26], complementing the results
obtained in our study with fathead minnow. Notably, neither the
total distance travelled nor the swimming speed were affected by
fluoxetine both in our study and in others performed on zebrafish
[26]. The anxiolytic responses observed in fish are also in full
agreement with the anxiolytic effects caused by fluoxetine
treatment in rodents [48,49] and humans [23,24], confirming
the high potentiality of fish models in translational biomedical
sciences.
An important aspect to consider for the determination of species
sensitivity to pharmaceuticals is the comparison of healthy animals
with humans affected by pathological conditions (e.g. clinical
depression). This difference should be taken into account since the
‘‘molecular landscape’’ of an individual with a pathological
condition will probably be different from that of a healthy one,
and this may change the sensitivity of a given endpoint to the same
concentration of drug. In this regard, a study performed by Wong
and collaborators [22] investigated the effects of a 2-week
fluoxetine exposure treatment on a specific strain of zebrafish,
the ‘‘High Stationary Behaviour’’ (HSB) line. This line is
characterized by high levels of stress and anxiety-related behav-
iours across multiple assays, including the Novel Tank Diving test,
in which it shows high stationary behaviour at the bottom of the
tank, and therefore less pronounced exploratory behaviour of the
top area [50]. The results showed that a concentration of 11 mg
fluoxetine/L was sufficient to significantly increase the time spent
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in the top half of the tank during the Novel Tank Diving Test,
suggesting that ‘‘anxious’’ zebrafish are more sensitive to
fluoxetine than the ‘‘healthy’’ fathead minnows used in our study
(LOEC: 11 mg/L vs 72 mg/L). This difference in sensitivity, which
could be drug-specific and species-specific, may have important
implications for the use of fish in pharmacological studies, as well
as for the risk assessment of pharmaceuticals in the environment,
since it implies that, from a Read-Across standpoint, healthy fish
may be less sensitive than mammal models or humans affected by
pathological conditions.
Both in fish and humans treated with fluoxetine it is possible to
identify responders and non-responders. In our study, the four
replicate fish groups could be divided into high-responders,
medium-responders and non-responders. Similarly to studies
performed in humans, no differences in drug plasma concentration
were observed among responders and non-responders [51]. The
explanation for the non-response are still unclear, and may well be
the results of a combination of factors including genetic
polymorphisms, subject-specific molecular etiology of the behav-
ioural disorder, and inter-individual variability in neurophysiology
and sensitivity to the treatment.
One of the main clinical challenges of SSRIs is the difficulty in
establishing which plasma concentrations produce the optimal
balance between antidepressant efficacy and tolerability. Several
studies have attempted this characterisation for fluoxetine, but
without success [51–53]. A similar difficulty in defining a clear
dose-response has been encountered for many other anti-
depressants, including citalopram [54], paroxetine [55], and
sertraline [56]. As Preskorn pointed out [32], one of the reasons
for these results could be the ‘‘signal-to-noise’’ problem created by
placebo responses, combined with the fact that those studies used
doses equal to or above the effective minimum dose, and therefore
examining only the plateau of the dose-response curve, where no
dose-response is expected. On the other hand, pharmacological
endpoints (e.g. serotonin uptake inhibition) clearly demonstrate the
concentration-dependent effects of SSRIs [32]. This discrepancy
in the observation of the dose-response may be due to several
reasons, including the ‘‘noise’’ created by self-consciousness and
social factors. In this context, it possible to argue that, unlike
humans, fish do not possess self-consciousness and therefore
placebo effects do not exist in this model. This implies a reduction
of the ‘‘noise’’ of the behavioural response, allowing a sharper
characterisation of the dose-response compared to human studies.
Indeed, our results demonstrated that fluoxetine induced a
concentration-related response in complex behaviour (i.e. anxiety)
only at concentrations similar or higher the effective HTPCs, with
no response at concentrations below the HTPCs, thus confirming
the parallelism between pharmacological and behavioural dose-
response.
Fluoxetine uptake and metabolism
Fluoxetine was metabolized to the equipotent metabolite,
norfluoxetine, in fish, as it is humans. In mammals, several
in vitro and in vivo studies have demonstrated that fluoxetine
metabolism involves several P450 (CYP) isoenzymes, including
CYP2D6, CYP2C9, and CYP3A4 [57]. Among these, no
orthologs to CYP2D6 and CYP2C9 have been identified in
fathead minnow or zebrafish, whereas CYP3A4 is highly
conserved in both species (92% and 94% of sequence identity to
the human protein, respectively) [58]. The difficulty in identifying
orthologs for the genes of the CYP2 family in fish was also
confirmed by Goldstone [59], who observed that when CYP genes
involved in the metabolism of xenobiotics are considered, inferring
the relationships between zebrafish and human genes is difficult,
mainly because of the whole genome duplication that occurred in
teleosts, and of the uneven gene duplication and gene loss that has
occurred in different species and gene lineages. This scenario
highlights the challenge in predicting the metabolism of human
pharmaceuticals in fish using the concept of conservation of
molecular pathways. In the case of fluoxetine, the enzymes
responsible for its metabolism in fish are yet to be characterized,
and in the context of the read-across, this implies that empirical
observations of the differences between the two species are the
only comparative option available at present.
Fluoxetine concentrations in fish plasma followed bi-phasic
kinetics. Plasma concentrations increased linearly between water
concentrations of 0.1 and 20 mg/L; however, between 20 and
72 mg/L the increase of fluoxetine in the plasma, though still
linear, was characterized by a sharp change in the slope of the
curve. Notably, the concentration of fluoxetine at which the slope
changed corresponded exactly to the decrease of the ratio
NFLX:FLX, indicating that at plasma concentrations of approx-
imately 100 ng/mL, the saturation and inhibitory effects of
fluoxetine on the enzymatic system that mediate its metabolism
started to play a major role in the pharmacokinetics. This effect is
also extensively documented in both humans and rodents
[48,60,61] and, although the identity of the enzymes converting
fluoxetine into norlfuoxetine is still unknown in fish, the similarity
of the saturation dynamics to the mammalian ones is striking.
Indeed, among SSRIs, fluoxetine was one of the strongest
inhibitors of human CYP2D6 in vivo [62,63]. This inhibition
was observed after daily administration of 20 mg fluoxetine for 3
weeks, which corresponded to a plasma concentration of
approximately 47 ng/mL. This value is, interestingly, close to
the range of fluoxetine concentration in fish plasma (40–100 ng/
mL) at which the inhibitory/saturation effects started to be
observable, suggesting that plasma concentrations of drug able
to inhibit and or saturate CYP2D6 (or its fish counterpart) may be
similar in both humans and fish.
Amsterdam and collaborators [51] measured the plasma
concentrations of fluoxetine and norfluoxetine in 615 patients
treated with 20 mg fluoxetine/day for 8 weeks, and observed a
FLX:NFLX ratio close to 1.0 (0.960.7), indicating that the levels
of circulating norfluoxetine are slightly higher than those of
fluoxetine. Our results indicated that fish can convert fluoxetine
into norfluoxetine in a more efficient way than humans, as shown
by the higher NFLX:FLX ratio. This may be due to a different
level of expression of the genes coding for the enzyme able to
metabolise fluoxetine or, alternatively, to different genetic
polymorphisms than the human counterpart.
In our study, we documented a significant inter-individual
variability in the plasma concentrations of fluoxetine and
norfluoxetine in fish exposed in the same tank to the same
concentration of drug (up to 7.6-fold for fluoxetine, and up to 4-
fold for norfluoxetine). As in fish, several studies reported a
significantly high inter-individual variability also in humans,
generally between 3- and 7-fold [64–66]. One of the possible
explanations for this variability may be the genetic polymorphisms
that can affect the catalytic activity of the CYP enzymes, leading to
the co-existence of poor metabolisers and ultra-rapid metabolisers
within the same population [57,67–69]. It is therefore possible to
infer that individuals with different degree of metabolic capacity
may be present in fish, as they are in humans.
Accuracy and applicability of the Fish Plasma Model
One of the major methodological challenges of this study was to
select water concentrations of fluoxetine able to produce, after 28
days of exposure, plasma concentrations of the drug that were
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respectively, below, equivalent, and above the HTPCs range. This
critical step for testing the Read-Across Hypothesis was successfully
achieved by applying the Fish Plasma Model. Only one other study
[70] has, to our knowledge, attempted to link plasma concentrations
to therapeutically-relevant effects in a laboratory study using fathead
minnow and the SSRI sertraline. In that study, however, all the tested
water concentrations produced plasma levels above the HTPC, hence
the Read-Across Hypothesis could not be fully tested.
In our study, the FPM generated highly accurate predictions for
the group exposed to 10 mg fluoxetine/L (Dmeasured-predicted = 14%).
The difference between predicted and measured concentrations
started increasing significantly in the group exposed to 20 mg
fluoxetine/L, in which measured values differed from the predicted
ones by 32%. However, if the intra-group variability of plasma
concentrations is considered (up to 3.5-fold), the FPM can still be
considered highly accurate.
This result confirmed the high potential of this simple steady-
state model to predict the bio-concentrations of pharmaceuticals in
fish plasma; however, a few notes of caution need to be provided.
Firstly, the accuracy of the prediction seems to be intimately
related to the accuracy of the estimation of the drug partitioning
factor (i.e. LogD7.4). Since experimental values are not always
available, the potential inaccuracy in the prediction of the
partitioning factor is reflected in the output of the FPM, and
further amplified by the logarithmic scale of the LogD values.
Secondly, considering the short-term duration of many exposure
studies performed on fish in laboratory set-ups, the actual steady-
state nature of the FPM will need to be carefully evaluated. In this
context it may be useful to compare the output of the FPM with
those of a physiologically-based-pharmacokinetics (PBPK) model
for the same compound, in order to better investigate the time-
dependency of the accumulation and the steady-state dynamics.
Finally, it is important to consider that the FPM is based on the
physiology of adult fish, therefore future research should also
address developing predictive models for the uptake of drugs in
fish embryos and larvae, which are highly sensitive life stages.
Understanding the factors driving the uptake of a drug into fish
plasma via the gills will provide additional clarification about the
reliability of the model, and help to define its domain of
applicability. Nevertheless, the FPM remains, at the moment, a
sensible starting point to guide the design of powerful experimental
designs by maximising the existing knowledge of the pharmacol-
ogy of the test compound.
Implications for the Environmental Risk Assessment of
pharmaceuticals
The concentration of pharmaceuticals in environmental ma-
trixes (e.g. water) has been so far one of the key factors in the ERA
process. However, environmental concentrations are only one
aspect, since it is the internal concentration of a drug (e.g. in the
blood or in a target tissue) that ultimately induces pharmacological
or toxicological responses in the organisms. Dramatic differences
can be observed in the uptake profile of pharmaceuticals present in
the water at the same concentration, even between different
chemical forms of the same parent compound, as is well
exemplified by glucocorticoids [11]. Understanding the factors
that affect uptake is clearly crucial, as one of the key questions is
whether the internal exposure levels are likely to be sufficient to
induce a biological response, and if yes at what level of biological
organization? In this context, the approach presented in this paper
provides a new powerful tool to risk assessors by shifting the
perspective from outside to inside the organism.
Our results demonstrate that the FPM can be reliably applied to
predict plasma concentrations of fluoxetine in environmental
realistic scenarios. Indeed, the range of water concentrations for
which the model was highly accurate fully covered the environ-
mentally relevant concentrations of fluoxetine, which are generally
in the range of few tens of ng/L. For example, Oakes et al. [19]
calculated Predicted Environmental Concentrations of fluoxetine
in Surface Water (PECSW) of 0.012 mg/L, 0.010 mg/L, and
0.059 mg/L for Germany, Sweden, and United Kingdom,
respectively. According to the FPM, the highest of these PEC
values (0.059 mg/L) would produce, in fish, plasma concentrations
approximately 1800-fold below the ones that in this study
produced significant effects on fish behaviour.
More than 30 papers have reported behavioural effects of
fluoxetine on fish [71]. The majority of those studies report
effective concentrations between 30 and 100 mg fluoxetine/L
[22,72], or higher [73,74]. These values can be fully explained by
the results obtained in our study, which provide a pharmacological
justification for the behavioural effects of fluoxetine on fish
reported in the literature.
Given the high cost of quantifying chemicals in environmental
matrixes (e.g. surface waters, effluent) and the point-like nature of
a similar environmental monitoring approach (samples represent a
snapshot of a very dynamic system) one could question the value
when considering the effects of pharmaceuticals that may take
days to reach effective concentrations. Recently hydrogeological
models able to predict water concentrations of pharmaceuticals in
European and US rivers have been developed and successfully
applied [75,76]. Combining this modelling approach with the use
of behaviour as new endpoint for eco-toxicological studies, it
would be possible to use the data obtained in our study and the
FPM predictions to translate the estimates of the hydrogeological
models (Predicted Environmental Concentration) into ‘‘maps of
risk’’ for fluoxetine-induced behavioural effects. In future research,
the same exercise may be performed also for other pharmaceuticals
whose effects on fish have been reliably characterised and for which
the applicability of the FPM has been demonstrated (e.g. sertraline),
and for any endpoint that is considered environmentally relevant in
adult fish (e.g. reproduction, growth, immunodepression). With the
increase of data availability, this approach may be also used for the
risk assessment of chemical mixtures [77], thus providing a
cumulative pharmacology-based risk assessment for mixtures of
compounds acting with the same Mode of Action (e.g. SSRIs).
Conclusions and Future Perspectives
Our study addressed the fundamental biological question of the
pharmacodynamic equivalence between animal species and
validated the Read-Across Hypothesis applied to the anti-
depressant fluoxetine. We demonstrated that healthy fish respond-
ed to the drug only when its plasma concentrations reached
plasma levels similar or higher than those effective in humans,
which may suggest that fish are less sensitive to fluoxetine than
humans. However, this apparently lower sensitivity could be at
least partly explained by the plausibly different sensitivity of
healthy individuals compared to pathologically affected ones, as
supported by the anxiolytic effects of fluoxetine observed in
experiments performed on a ‘‘anxious strain’’ of zebrafish [22]. In
light of these results, the overall sensitivity of fish to fluoxetine is
not so dissimilar from that of patients affected, for example, by
general anxiety disorders. Moreover, these results highlight the
importance of using the right model in different extrapolation
scenarios. For example, whilst healthy fish are appropriate in the
ERA context, disease models may be more suitable for refined pre-
clinical safety applications.
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We demonstrated that anchoring the interpretation of pharma-
cological and toxicological effects to the internal concentrations of
pharmaceuticals provides a quantitative benchmark to perform
qCSE. Considering the importance of this aspect, future research
should be addressed at improving our understanding of absorp-
tion, distribution, metabolism, and excretion (ADME) processes in
fish in order to enhance the translational power of the qCSE. The
validation of the Read-Across Hypothesis also for other pharma-
ceuticals may foster the use of fish models in toxicological and
pharmacological disciplines, and thanks to its quantitative features,
the Read-Across approach could be easily integrated with the
recently proposed Adverse Outcome Pathway approach [78] to
develop a powerful pharmacology-informed tool for the prediction
of pharmacological and toxicological effects in fish models.
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